Personalis Selected by the LSU Health New Orleans Precision Medicine Program to Provide Comprehensive Clinical Genomic Testing for Cancer and Inherited Genetic Disease

Menlo Park, CA – November 17, 2015 – Personalis, Inc., a leading genomics-based clinical diagnostic laboratory, announced today that the company has entered into a partnership with the Louisiana State University Health Sciences Center New Orleans Precision Medicine Program to provide comprehensive clinical genomic testing for tumor-profiling and inherited genetic disease. “We are thrilled to work together with the LSU Health New Orleans Precision Medicine Program to provide our comprehensive, high accuracy genomic tests to their patients with cancer and genetic disorders. Working with LSU Health New Orleans, we want to provide the best possible care to patients by bringing genomics-based precision medicine to the bedside,” said Dr. Richard Chen, Chief Scientific Officer at Personalis. “Not only will this partnership bring benefits to patients, but it will also bring the substantial medical and scientific expertise at the two institutions together in a research capacity that will benefit future patients.”

Personalis will perform clinical cancer testing and research services through its ACE CancerPlus test. As the largest and most comprehensive cancer panel available today, the ACE CancerPlus test combines both DNA and RNA sequencing of over 1,300 genes and utilizes Personalis’ proprietary ACE technology to provide leading edge coverage and accuracy. Personalis’ testing will provide comprehensive tumor genomic profile data to guide therapy and ongoing research at the LSU Health New Orleans Precision Medicine Program. In addition, Personalis will provide its ACE Clinical Exome™ test for the diagnosis of genetic disorders in both pediatric and adult patients. The ACE Clinical Exome Test targets essentially all human genes using Personalis’ leading ACE exome technology. Through a multifaceted approach, including an augmented exome sequencing platform, improved informatics, and genome-wide sequence-based structural variant detection, Personalis achieves improved diagnostic yield.

“We serve as a central health care provider to a large and diverse population in Louisiana that has an equally diverse set of clinical diagnostic needs,” said Dr. Larry Hollier, Chancellor, LSU Health Sciences Center New Orleans. “We have often seen that conventional genetic diagnostic methods have been unable to provide comprehensive results, and we feel Personalis’ sophisticated approach is the future in terms of genome-scale diagnostics for inherited genetic diseases and for cancer. Our partnership with Personalis will enable us to provide the most advanced genomics tests to our patients.”

“We are very excited to be working with LSU Health New Orleans and the Precision Medicine Program on Mendelian and cancer diagnostics as well as supporting certain research efforts associated with the LSU Health New Orleans Precision Medicine Program,” said John West, CEO of Personalis. “They are at the forefront of adopting advanced genomic diagnostics for clinical care, and understand the complexities and clinical value of comprehensive and accurate analysis and interpretation.”

“The LSU Health New Orleans School of Medicine is strongly committed to clinical and translational research, particularly focused on conditions affecting the patients we serve,” noted Dr. Steve Nelson, Dean of LSU Health New Orleans School of Medicine. “The partnership with Personalis will open the way to cutting edge investigations of cancers and genetic disorders that disproportionately affect Louisiana patients.” Dr. Lucio Miele, Professor and Chair, Department of Genetics at LSU Health New Orleans School of Medicine, commented that, “Personalis and the LSU Health New Orleans Precision Medicine Program will also collaborate on various research projects that will be focused on enhancing patient care and outcomes, including the areas of immuno-oncology and liquid biopsies.”

“We look forward to a productive partnership that will result in better care for our patients and their families, especially those who have struggled to find answers that now may be within reach,” concluded LSU Health New Orleans Chancellor Dr. Hollier.

About Personalis, Inc.

Personalis, Inc. (www.personalis.com) is a leading precision medicine company focused on advanced NGS-based clinical diagnostic, clinical trial and research services for cancer and inherited genetic disease.  Personalis also provides DNA sequencing and data analysis of human genomes.

The Personalis ACE Exome and Transcriptome technology is designed to obtain the most comprehensive and accurate tumor molecular profile for immuno-oncology applications. The company’s clinical laboratory is GCP compliant, CLIA licensed and CAP accredited.

Media Contact for Personalis:

Jennifer Havlek
pr@personalis.com
www.personalis.com
650-752-1300

About LSUHSC

LSU Health Sciences Center New Orleans educates Louisiana’s health care professionals. The state’s health university leader, LSU Health New Orleans includes a School of Medicine, the state’s only School of Dentistry, Louisiana’s only public School of Public Health, and Schools of Allied Health Professions, Nursing, and Graduate Studies. LSU Health New Orleans faculty takes care of patients in public and private hospitals and clinics throughout the region. In the vanguard of biosciences research in a number of areas in a worldwide arena, the LSU Health New Orleans research enterprise generates jobs and enormous economic impact. LSU Health New Orleans faculty have made lifesaving discoveries and continue to work to prevent, advance treatment, or cure disease. To learn more, visit www.lsuhsc.edu, twitter.com/LSUHSCHealth or facebook.com/LSUHSC.

About the LSU Health New Orleans Center for Precision Medicine

The NCI-funded Gulf South National Institute of Health Community Oncology Research Program (NCORP), led by Dr. Augusto Ochoa, is designed to allow NCORP investigators to design genomics-based clinical trials tailored to Louisiana and Mississippi patients.

2017-08-21T22:57:20+00:00